Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S STOKESBERRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1427032234
CMS profile
19736
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,843.60

97 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,833.12 96
Education $10.48 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S STOKESBERRY

NPI 1427032234 · CMS profile ID 19736

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427032234?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

97 matching records · $1,843.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 97 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–97 of 97.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $15.7708/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233636898 CMS
QOL Medical, LLC $23.9008/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185024204 CMS
ABBVIE INC. $20.9308/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419363 CMS
Janssen Biotech, Inc. $15.7907/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174437813 CMS
ABBVIE INC. $8.1307/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419359 CMS
Janssen Biotech, Inc. $17.2407/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174438093 CMS
Pharmacosmos Therapeutics Inc. $19.6807/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250731062 CMS
ABBVIE INC. $18.9107/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419355 CMS
Janssen Biotech, Inc. $12.2807/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174440703 CMS
ABBVIE INC. $19.0907/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419351 CMS
Intercept Pharmaceuticals, Inc. $19.1507/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249870328 CMS
Lilly USA, LLC $27.3807/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186594718 CMS
ABBVIE INC. $14.3707/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419347 CMS
ABBVIE INC. $22.4506/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419343 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.1406/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223833867 CMS
Gilead Sciences, Inc. $13.8206/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234578422 CMS
Janssen Biotech, Inc. $15.2406/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174439463 CMS
Aimmune Therapeutics, Inc. $26.9906/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249680119 CMS
ABBVIE INC. $11.0106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419338 CMS
ABBVIE INC. $20.6505/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419331 CMS
ABBVIE INC. $17.0105/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419335 CMS
Janssen Pharmaceuticals, Inc $10.4805/28/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174791524 CMS
Ipsen Biopharmaceuticals, Inc $17.8805/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208825939 CMS
ABBVIE INC. $12.2805/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419329 CMS
Lilly USA, LLC $29.0805/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186643901 CMS
Janssen Biotech, Inc. $12.6805/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174429611 CMS
Janssen Biotech, Inc. $3.4505/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174439335 CMS
Janssen Biotech, Inc. $15.3105/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174443276 CMS
Janssen Biotech, Inc. $11.7605/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174430367 CMS
ABBVIE INC. $5.5504/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419325 CMS
ABBVIE INC. $21.2804/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419320 CMS
ABBVIE INC. $13.1604/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419315 CMS
Dynavax Technologies Corporation $20.8904/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1182981153 CMS
Lilly USA, LLC $28.0804/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186594720 CMS
ABBVIE INC. $14.2303/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419311 CMS
Phathom Pharmaceuticals, Inc. $7.5503/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219337304 CMS
ABBVIE INC. $17.1403/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419307 CMS
Lilly USA, LLC $19.9103/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186606532 CMS
Madrigal Pharmaceuticals $24.1503/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248313908 CMS
ABBVIE INC. $15.3003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419299 CMS
ABBVIE INC. $13.6003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419303 CMS
Celltrion USA Inc. $25.7403/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250832905 CMS
ABBVIE INC. $7.8302/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419292 CMS
ABBVIE INC. $6.8802/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204419295 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.5602/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223878585 CMS
Aimmune Therapeutics, Inc. $22.2202/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249680117 CMS
Madrigal Pharmaceuticals $27.5101/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248313906 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51.29 5
PY2020 $197.03 5
PY2021 $249.67 10
PY2022 $93.99 7
PY2024 $99.26 5
PY2025 $1,843.60 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $108,902.60 28
PY2024 Principal investigator $94,981.85 42
PY2023 Principal investigator $412,886.37 49
PY2022 Principal investigator $102,314.36 32
PY2021 Principal investigator $163,880.82 41
PY2020 Principal investigator $333,675.73 83
PY2019 Recipient $39,889.86 5
PY2019 Principal investigator $462,244.42 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $4,418.65 11/04/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202520673
Principal investigator 1 Genentech, Inc. $1,200.00 10/10/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596833
Principal investigator 1 Genentech, Inc. $1,500.00 10/01/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596837
Principal investigator 1 ABBVIE INC. $1,212.80 09/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202507517
Principal investigator 1 ABBVIE INC. $2,715.00 09/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202507519
Principal investigator 1 ABBVIE INC. $2,115.00 09/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202507521
Principal investigator 1 ABBVIE INC. $486.20 07/02/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202494813
Principal investigator 1 ABBVIE INC. $1,676.80 07/02/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202494815
Principal investigator 1 ABBVIE INC. $1,498.00 06/13/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202491477
Principal investigator 1 ABBVIE INC. $7,523.85 06/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202488291
Principal investigator 1 ABBVIE INC. $3,600.60 06/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202488293
Principal investigator 1 Genentech, Inc. $2,038.00 05/28/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596827
Principal investigator 1 ABBVIE INC. $3,313.10 05/07/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202482337
Principal investigator 1 ABBVIE INC. $1,621.40 05/06/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202481109
Principal investigator 1 ABBVIE INC. $8,240.80 04/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202469409
Principal investigator 1 ABBVIE INC. $12,330.05 04/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202469413
Principal investigator 1 ABBVIE INC. $428.00 04/03/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202469416
Principal investigator 1 Genentech, Inc. $2,038.00 03/21/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596816
Principal investigator 1 ABBVIE INC. $1,212.80 03/06/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202456501
Principal investigator 1 ABBVIE INC. $1,628.40 03/06/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202456538
Principal investigator 1 ABBVIE INC. $50.00 02/05/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202445125
Principal investigator 1 Genentech, Inc. $16,304.00 01/22/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596812
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,748.85 01/16/2025 Non-covered Recipient Entity
Digestive Disease Specialists
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1235997679
Principal investigator 1 Genentech, Inc. $7,133.00 01/14/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596820
Principal investigator 1 Genentech, Inc. $1,019.00 01/14/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211596824
Principal investigator 1 ABBVIE INC. $1,500.00 01/10/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis No dispute reported 06/30/2026 1202438038
Principal investigator 1 ABBVIE INC. $1,735.10 01/02/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202433465
Principal investigator 1 ABBVIE INC. $1,615.20 01/02/2025 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202434938